Routine Gene Testing For Plavix Patients Unsupported By Evidence - ACC/AHA
This article was originally published in The Pink Sheet Daily
Executive Summary
While a small minority of cardiologists has embraced genetic testing for clopidogrel, FDA's warning that 2% - 14% of patients may not respond caused pushback from many in the field who argue it is not clear what steps to take when a patient is identified as a poor metabolizer.
You may also be interested in...
Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed
The first regulatory application for a point-of-care assay for genotyping patients for response to antiplatelet therapy was submitted at the end of August - if Nanosphere's test is approved, it could make genotyping a more feasible routine tool for guiding therapy for Plavix
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.